Treg Therapies in Autoimmune Diseases Report
Recent advancements in Cell Therapy technologies have shown promise in the treatment of autoimmune diseases. Specifically non-engineered Regulated T cell (Treg) therapies have increased in popularity, due to their broad immune suppression, lower off-target risk, and manufacturing scalability.
The report offers insight into:
- Drug Status: 59% of Treg therapies are at the preclinical stage, reflecting strong early-phase activity
- Disease Breakdown: Graft-versus-host disease the most studies Indication
- Top Targets: IL-2 and HLA-A2 most common, for the prevention of transplant rejection
- Deals: $7.31B in deal value over the last decade, including a $2.09B collaboration between AstraZeneca and Quell Therapeutics
You May Also Be Interested In…
Learn More About Autoimmune
What is Beacon Autoimmune?
- The Most Comprehensive Way to Search the Autoimmune Drug Development Landscape: Unique search ontologies based on Autoimmune drug and trial characteristics
- Market Leading Approach to Autoimmune Preclinical & Clinical Data Curation: Manual curation of key Autoimmune research and development data points by Autoimmune research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Autoimmune company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
